BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Sells $162,760.00 in Stock
BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Sells $162,760.00 in Stock
BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) CMO Todd Berard sold 6,500 shares of the company's stock in a transaction dated Wednesday, January 18th. The stock was sold at an average price of $25.04, for a total value of $162,760.00. Following the sale, the chief marketing officer now owns 119,265 shares in the company, valued at approximately $2,986,395.60. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
生物生命解决方案公司(纳斯达克代码：BLFS-GET Rating)首席营销官托德·贝拉德在日期为1月18日星期三的交易中出售了6,500股该公司股票。这只股票的平均售价为25.04美元，总价值为162,760.00美元。出售后，首席营销官现在拥有119,265股公司股票，价值约2,986,395.60美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过美国证券交易委员会网站.
Todd Berard also recently made the following trade(s):
托德·贝拉德最近还进行了以下交易：
- On Wednesday, December 28th, Todd Berard sold 501 shares of BioLife Solutions stock. The stock was sold at an average price of $16.90, for a total value of $8,466.90.
- On Thursday, November 10th, Todd Berard sold 50 shares of BioLife Solutions stock. The shares were sold at an average price of $23.16, for a total value of $1,158.00.
- 12月28日，星期三，托德·贝拉德出售了501股BioLife Solutions股票。这只股票的平均售价为16.90美元，总价值为8466.90美元。
- 11月10日，星期四，托德·贝拉德出售了50股BioLife Solutions的股票。这些股票的平均价格为23.16美元，总价值为1158.00美元。
BioLife Solutions Trading Up 2.4 %
BioLife Solutions股价上涨2.4%
NASDAQ:BLFS opened at $24.45 on Monday. The stock's 50 day moving average price is $20.35 and its 200 day moving average price is $21.18. The company has a market capitalization of $1.05 billion, a PE ratio of -9.86 and a beta of 1.75. The company has a quick ratio of 2.76, a current ratio of 3.68 and a debt-to-equity ratio of 0.06. BioLife Solutions, Inc. has a 52-week low of $10.40 and a 52-week high of $31.11.
纳斯达克：周一开盘报24.45美元。该股的50日移动均线价格为20.35美元，200日移动均线价格为21.18美元。该公司市值10.5亿美元，市盈率为-9.86，贝塔系数为1.75。该公司的速动比率为2.76，流动比率为3.68，债务权益比为0.06。BioLife Solutions，Inc.的股价为10.40美元，为52周低点，52周高点为31.11美元。
Institutional Trading of BioLife Solutions
生物生命解决方案的制度性交易
A number of hedge funds have recently added to or reduced their stakes in the stock. Public Sector Pension Investment Board lifted its position in BioLife Solutions by 1.0% during the 2nd quarter. Public Sector Pension Investment Board now owns 56,525 shares of the medical equipment provider's stock worth $781,000 after acquiring an additional 565 shares during the period. Texas Permanent School Fund lifted its position in BioLife Solutions by 3.0% during the 2nd quarter. Texas Permanent School Fund now owns 21,901 shares of the medical equipment provider's stock worth $302,000 after acquiring an additional 642 shares during the period. Macquarie Group Ltd. lifted its position in BioLife Solutions by 1.1% during the 2nd quarter. Macquarie Group Ltd. now owns 73,437 shares of the medical equipment provider's stock worth $1,014,000 after acquiring an additional 766 shares during the period. Mutual of America Capital Management LLC lifted its position in BioLife Solutions by 18.7% during the 2nd quarter. Mutual of America Capital Management LLC now owns 5,128 shares of the medical equipment provider's stock worth $71,000 after acquiring an additional 808 shares during the period. Finally, Jane Street Group LLC lifted its position in BioLife Solutions by 6.9% during the 1st quarter. Jane Street Group LLC now owns 13,377 shares of the medical equipment provider's stock worth $304,000 after acquiring an additional 858 shares during the period. 89.82% of the stock is owned by institutional investors and hedge funds.
一些对冲基金最近增持或减持了该股。公共部门养老金投资委员会在第二季度将其在BioLife Solutions的头寸提高了1.0%。公共部门养老金投资委员会现在拥有这家医疗设备提供商的56,525股股票，价值78.1万美元，在此期间又购买了565股。德克萨斯永久学校基金在第二季度将其在BioLife Solutions的头寸提高了3.0%。德克萨斯永久学校基金在此期间额外购买了642股，现在拥有21,901股这家医疗设备提供商的股票，价值30.2万美元。麦格理集团(Macquarie Group Ltd.)在第二季度将其在BioLife Solutions的头寸提高了1.1%。麦格理集团(Macquarie Group Ltd.)在此期间增持了766股，目前持有73,437股这家医疗设备供应商的股票，价值1,014,000美元。美国互惠资本管理公司在第二季度将其在BioLife Solutions的头寸提高了18.7%。美国互惠资本管理有限责任公司在此期间额外收购了808股，现在拥有这家医疗设备提供商价值71,000美元的5,128股股票。最后，简街集团在第一季度将其在BioLife Solutions的头寸提高了6.9%。简街集团现在拥有这家医疗设备提供商13,377股股票，价值304,000美元，在此期间又购买了858股。89.82%的股票由机构投资者和对冲基金持有。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
A number of research analysts have recently commented on BLFS shares. Stephens dropped their price objective on BioLife Solutions to $31.00 in a report on Wednesday, November 16th. StockNews.com upgraded BioLife Solutions to a "sell" rating in a report on Monday, November 21st.
一些研究分析师最近对BLFS的股票发表了评论。斯蒂芬斯在11月16日星期三的一份报告中将BioLife Solutions的目标价下调至31.00美元。在11月21日星期一的一份报告中，StockNews.com将BioLife Solutions的评级上调至“卖出”。
BioLife Solutions Company Profile
BioLife Solutions公司简介
(Get Rating)
(获取评级)
BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
BioLife Solutions，Inc.为美国、加拿大、欧洲、中东、非洲和国际上的细胞和基因治疗行业开发、制造和提供生物生产工具和服务。该公司的产品用于基础和应用研究，以及基于生物的疗法的商业制造。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on BioLife Solutions (BLFS)
- CVS Health is Growing into an Integrated Healthcare Organization
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
- 免费获取StockNews.com关于BioLife解决方案的研究报告(BLFS)
- CVS Health正在成长为一家综合医疗保健组织
- NVIDIA前景改善：2023年候选观察名单
- C3.ai Stock是ChatGPT人工智能的玩法吗？
- 2023年你应该购买哪些无线股票？
- 维珍银河股票准备起飞了吗？
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
每日收到有关BioLife解决方案的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对BioLife Solutions和相关公司的最新新闻和分析师评级的每日简要摘要。